改善 CAR-T 细胞治疗对病毒性疾病、癌症和自身免疫性疾病疗效的分子机制最新进展

Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases.

实体瘤过继性细胞治疗后生存结局和急性毒性的临床决定因素

Clinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumors.

CRP 和肺功能等基线参数可能有助于识别实体瘤细胞治疗期间不良结局和毒性风险较高的患者，值得前瞻性评估。

CAR-T 细胞治疗的机制、优化策略和挽救方案

Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy.

CAR 细胞治疗耐药：机制与克服策略

Resistance to CAR-based cell therapy: Mechanisms and overcoming strategies.

可编程工程菌调控代谢并原位重塑 TME 以增强过继性细胞治疗

Programmable engineered bacteria manipulate metabolism and remodel the TME in situ for enhancing adoptive cell therapy.

CAR-T 细胞治疗指南：研发、现状与未来前景

A guide to CAR T cell therapies: development, current status and future prospects.

CAR-T 细胞治疗诱导的心脏毒性：病理生理机制与药物干预策略

Chimeric antigen receptor-T cell therapy-induced cardiotoxicity: Pathophysiological mechanisms and pharmacological intervention strategies.

髓系细胞在 CAR-T 细胞治疗中的矛盾作用

The Conflicting Role of Myeloid Cells in CAR T-Cell Therapy.

固有免疫与固有样免疫细胞的 CAR 工程化：实体瘤过继细胞治疗的新视野

CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors.

CAR 工程化的固有免疫细胞和固有样免疫细胞代表了有前景的下一代策略，可克服传统 CAR-T 疗法在实体瘤中的局限性。其中，CAR-NKT 和 CAR-T 细胞可能为临床转化提供特殊优势，值得在未来试验中进一步研究。

释放 CAR-NK 细胞治疗实体瘤的潜力：挑战、创新与免疫治疗的未来前沿

Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy.